Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CYP-1020 · BL-1020

Small molecule · developed by BioLineRx

Phase 2/3 Most advanced trial (none active)

BLRX Developer

1 Registered trials

What is CYP-1020?

CYP-1020 is an orally available small molecule studied in schizophrenia and cognitive effects in schizophrenic patients.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: BL-1020
Drug type: Small molecule
Therapy area: Psychiatry
Developer: BioLineRx, Ltd. (BLRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: K1WO7H97QZ

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01363349	Phase 2/3	Schizophrenia	Terminated	BLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cognitive Effect on Schizophrenic PatientsSchizophrenia

More from BioLineRx

BL-1020 Phase 2 BL-1021 Phase 1 BL-7010 Phase 1/2 BL-7040 Phase 2

Sources

ClinicalTrials.gov NCT01363349

Updated Oct 3, 2026. Something wrong or missing? Report it on the BLRX page.

Follow BLRX, the company behind CYP-1020

See BLRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BLRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z